Literature DB >> 31732918

Interaction Between Diabetes Mellitus and Platelet Reactivity in Determining Long-Term Outcomes Following Percutaneous Coronary Intervention.

Fabio Mangiacapra1, Edoardo Bressi2, Iginio Colaiori2, Elisabetta Ricottini2, Ilaria Cavallari2, Marialessia Capuano2, Michele Matia Viscusi2, Silvia Spoto3, Emanuele Barbato4, Germano Di Sciascio2.   

Abstract

Diabetes mellitus (DM) is an independent predictor of adverse outcomes in patients with coronary artery disease (CAD). We investigated the interaction between DM and high platelet reactivity (HPR) in determining long-term clinical outcomes after percutaneous coronary intervention (PCI). We enrolled 500 patients who were divided based on the presence of DM and HPR. Primary endpoint was the occurrence of major adverse clinical events (MACE) at 5 years. Patients with both DM and HPR showed the highest estimates of MACE (37.9%, log-rank p < 0.001), all-cause death (15.5%, log-rank p = 0.022), and non-fatal myocardial infarction (25.9%, log-rank p < 0.001). At Cox proportional hazard analysis, the coexistence of DM and HPR was an independent predictor of MACE (HR 3.46, 95% CI 1.67-6.06, p < 0.001). Among patients with stable CAD undergoing elective PCI and treated with aspirin and clopidogrel, the combination of DM and HPR identifies a cohort of patients with the highest risk of MACE at 5 years.

Entities:  

Keywords:  Coronary artery disease; Diabetes mellitus; Percutaneous coronary intervention; Platelet function

Year:  2019        PMID: 31732918     DOI: 10.1007/s12265-019-09931-z

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN: 1937-5387            Impact factor:   4.132


  1 in total

1.  Association of dipeptidyl peptidase IV polymorphism, serum lipid profile, and coronary artery stenosis in patients with coronary artery disease and type 2 diabetes.

Authors:  Zhongsu Wang; Yang Liu; Weizong Wang; Haiyan Qu; Yi Han; Yinglong Hou
Journal:  Medicine (Baltimore)       Date:  2021-04-02       Impact factor: 1.817

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.